The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...

After months of discussion, President Donald Trump’s new direct-to-consumer pharmaceutical site, TrumpRx, officially launched ...

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy ...

Eli Lilly (NYSE: LLY) stock bounced back 2.4% by 9:50 a.m. ET Monday after taking a tumble last week.

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months. In large part, that rebound was fueled ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...